142 related articles for article (PubMed ID: 37026953)
1. Cardiometabolic multimorbidity may identify a more severe subset of rheumatoid arthritis, results from a "real-life" study.
Ruscitti P; Di Muzio C; Conforti A; Di Cola I; Pavlych V; Navarini L; Currado D; Biaggi A; Di Donato S; Marino A; Lorusso S; Ursini F; Giacomelli R; Cipriani P
Medicine (Baltimore); 2023 Apr; 102(14):e33362. PubMed ID: 37026953
[TBL] [Abstract][Full Text] [Related]
2. Comparisons between comorbid conditions and health care consumption in rheumatoid arthritis patients with or without biological disease-modifying anti-rheumatic drugs: a register-based study.
Bengtsson K; Jacobsson LT; Rydberg B; Kvist G; Torstenson T; Dehlin M; Hilme E; Lindhé A; Wallerstedt SM; Forsblad-d'Elia H
BMC Musculoskelet Disord; 2016 Dec; 17(1):499. PubMed ID: 27955647
[TBL] [Abstract][Full Text] [Related]
3. Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity: Single center real life results.
Armagan B; Sari A; Erden A; Kilic L; Erdat EC; Kilickap S; Kiraz S; Bilgen SA; Karadag O; Akdogan A; Ertenli I; Kalyoncu U
Medicine (Baltimore); 2018 Mar; 97(13):e9930. PubMed ID: 29595700
[TBL] [Abstract][Full Text] [Related]
4. Treatment Patterns of Multimorbid Patients with Rheumatoid Arthritis: Results from an International Cross-sectional Study.
Radner H; Yoshida K; Hmamouchi I; Dougados M; Smolen JS; Solomon DH
J Rheumatol; 2015 Jul; 42(7):1099-104. PubMed ID: 26034147
[TBL] [Abstract][Full Text] [Related]
5. Clinical predictors of multiple failure to biological therapy in patients with rheumatoid arthritis.
Novella-Navarro M; Plasencia C; Tornero C; Navarro-Compán V; Cabrera-Alarcón JL; Peiteado-López D; Nuño L; Monjo-Henry I; Franco-Gómez K; Villalba A; Balsa A
Arthritis Res Ther; 2020 Dec; 22(1):284. PubMed ID: 33298140
[TBL] [Abstract][Full Text] [Related]
6. Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis.
Santiago-Casas Y; González-Rivera TC; Castro-Santana LE; Ríos G; Martínez D; Rodríguez VE; González-Alcover R; Mayor AM; Vilá LM
Ethn Dis; 2010; 20(1 Suppl 1):S1-191-5. PubMed ID: 20521413
[TBL] [Abstract][Full Text] [Related]
7. Identifying markers of sustained remission in rheumatoid arthritis patients on long-term tapered biological disease-modifying antirheumatic drugs.
Valor L; Garrido J; Martínez-Estupiñán L; Hernández-Flórez D; Janta I; López-Longo FJ; Monteagudo I; González CM; Naredo E
Rheumatol Int; 2018 Aug; 38(8):1465-1470. PubMed ID: 29915991
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study.
Naranjo A; Sokka T; Descalzo MA; Calvo-Alén J; Hørslev-Petersen K; Luukkainen RK; Combe B; Burmester GR; Devlin J; Ferraccioli G; Morelli A; Hoekstra M; Majdan M; Sadkiewicz S; Belmonte M; Holmqvist AC; Choy E; Tunc R; Dimic A; Bergman M; Toloza S; Pincus T;
Arthritis Res Ther; 2008; 10(2):R30. PubMed ID: 18325087
[TBL] [Abstract][Full Text] [Related]
9. ACPA Antibodies Titer at the Time of Rheumatoid Arthritis Diagnosis Is Not Associated with Disease Severity.
Shpatz R; Braun-Moscovici Y; Balbir-Gurman A
Isr Med Assoc J; 2021 Oct; 23(10):646-650. PubMed ID: 34672447
[TBL] [Abstract][Full Text] [Related]
10. Pathogenesis, clinical features, and treatment strategy for rheumatoid arthritis-associated interstitial lung disease.
Akiyama M; Kaneko Y
Autoimmun Rev; 2022 May; 21(5):103056. PubMed ID: 35121155
[TBL] [Abstract][Full Text] [Related]
11. Biologic refractory disease in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.
Kearsley-Fleet L; Davies R; De Cock D; Watson KD; Lunt M; Buch MH; Isaacs JD; Hyrich KL;
Ann Rheum Dis; 2018 Oct; 77(10):1405-1412. PubMed ID: 29980575
[TBL] [Abstract][Full Text] [Related]
12. [Survival of bDMARDs in bionaive patients with rheumatoid arthritis: data from a retrospective 12-month follow-up].
Aronova ES; Lukina GV; Glukhova SI; Gridneva GI; Kudryavtseva AV
Ter Arkh; 2020 Jun; 92(5):39-45. PubMed ID: 32598774
[TBL] [Abstract][Full Text] [Related]
13. Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for the treatment of rheumatoid arthritis not previously treated with disease-modifying antirheumatic drugs and after the failure of conventional disease-modifying antirheumatic drugs only: systematic review and economic evaluation.
Stevenson M; Archer R; Tosh J; Simpson E; Everson-Hock E; Stevens J; Hernandez-Alava M; Paisley S; Dickinson K; Scott D; Young A; Wailoo A
Health Technol Assess; 2016 Apr; 20(35):1-610. PubMed ID: 27140438
[TBL] [Abstract][Full Text] [Related]
14. Factors associated with the achievement of biological disease-modifying antirheumatic drug-free remission in rheumatoid arthritis: the ANSWER cohort study.
Hashimoto M; Furu M; Yamamoto W; Fujimura T; Hara R; Katayama M; Ohnishi A; Akashi K; Yoshida S; Nagai K; Son Y; Amuro H; Hirano T; Ebina K; Uozumi R; Ito H; Tanaka M; Ohmura K; Fujii T; Mimori T
Arthritis Res Ther; 2018 Aug; 20(1):165. PubMed ID: 30075810
[TBL] [Abstract][Full Text] [Related]
15. Real-world patient characteristics and use of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis: a cross-national study.
Ingrasciotta Y; Jin Y; Foti SS; Landon JE; Tari M; Mattace-Raso F; Kim SC; Trifirò G
Clin Rheumatol; 2023 Apr; 42(4):1047-1059. PubMed ID: 36534353
[TBL] [Abstract][Full Text] [Related]
16. The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study.
An Y; Liu T; He D; Wu L; Li J; Liu Y; Bi L; Zhou B; Lin C; He L; Liu X; Li X; Yang N; Zhang Z; Song H; Wei W; Liu J; Bi Y; Li Z
Clin Rheumatol; 2017 Jan; 36(1):35-43. PubMed ID: 27709444
[TBL] [Abstract][Full Text] [Related]
17. Influence of baseline modified Rheumatic Disease Comorbidity Index (mRDCI) on drug survival and effectiveness of biological treatment in patients affected with Rheumatoid arthritis, Spondyloarthritis and Psoriatic arthritis in real-world settings.
Iannone F; Salaffi F; Fornaro M; Di Carlo M; Gentileschi S; Cantarini L; Lopalco G
Eur J Clin Invest; 2018 Nov; 48(11):e13013. PubMed ID: 30079593
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular risk comorbidities in rheumatoid arthritis patients and the use of anti-rheumatic drugs: a cross-sectional real-life study.
Vicente GNS; Pereira IA; de Castro GRW; da Mota LMH; Carnieletto AP; de Souza DGS; da Gama FO; Santos ABV; de Albuquerque CP; Bértolo MB; Júnior PL; Giorgi RDN; Radominski SC; Guimarães MFBR; Bonfiglioli KR; Sauma MFLDC; Brenol CV; da Rocha Castelar Pinheiro G
Adv Rheumatol; 2021 Jun; 61(1):38. PubMed ID: 34172097
[TBL] [Abstract][Full Text] [Related]
19. Low rates of biologic-free clinical disease activity index remission maintenance after biologic disease-modifying anti-rheumatic drug discontinuation while in remission in a Japanese multicentre rheumatoid arthritis registry.
Yoshida K; Kishimoto M; Radner H; Matsui K; Okada M; Saeki Y; Solomon DH; Tohma S
Rheumatology (Oxford); 2016 Feb; 55(2):286-90. PubMed ID: 26350484
[TBL] [Abstract][Full Text] [Related]
20. Tofacitinib for Treating Rheumatoid Arthritis After the Failure of Disease-Modifying Anti-rheumatic Drugs: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Uttley L; Bermejo I; Ren S; Martyn-St James M; Wong R; Scott DL; Young A; Stevenson M
Pharmacoeconomics; 2018 Sep; 36(9):1063-1072. PubMed ID: 29546668
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
